Newsletter Research CT Opps Banner.jpg
 
 

In this email:

  1. Research News and Opportunities
  2. Get Involved
  3. Recent GAAPP Publications and Conference Presentations
  4. Relevant News
  5. From the Chief Scientific Officer Desk
 
 

 
 

Research News and Opportunities

 
 

Recruitment.jpg

Recruiting Research Opportunities

Bronchiectasis Understanding and Research on Daily Experiences and Needs or The BURDEN initiative is a research project to examine the impact of Non-Cystic Fibrosis Bronchiectasis (NCFBE) on the everyday life of people living with NCFBE and their caregivers. It is also commonly referred to as bronchiectasis (without cystic fibrosis) or just bronchiectasis. Bronchiectasis is a chronic, often progressive lung disease characterized by irreversible and abnormal widening of the bronchi and chronic symptoms.

For more information, click here!

Please let us know if you or someone in your community is a good match for this. For more information on GAAPP projects that are recruiting: research@gaapp.org

 
 

 
 

Get Involved

 
 

449260473_120210630697420412_5034504310825573757_n.jpg

World Bronchiectasis Day Research Webinar

World Bronchiectasis Day webinar, that explored the value of patient engagement in research, is available now!

GAAPP brought together an expert in her field and a patient ambassador in conversation. Listen to Dr. Michal Shteinberg, M.D., PhD. And Ninon Farber as they discussed Ninon’s journey through her struggle with bronchiectasis and the value she found in participating in research. Find out how you as a patient can engage in research.

Hebrew version: https://youtu.be/sT2o7tBpKHM
English version: https://youtu.be/7jhPNRHqmJo

Click here to watch the whole webinar!

 
 

 
 

GAAPP Publications and Conference Presentations

 
 
GAAPP publciations.png

GAAPP will be presenting collaborative data at two upcoming major  European conferees:

  • At the European Respiratory Society Congress in Vienna from 7 to 11 September 2024 we will shine a light on “Multi-morbidity in Type 2 Disease: A Patient and Providers Survey.”

 
 
  • At the European Academy of Dermatology and Venereology Congress in Amsterdam from 25 to 28 September 2024 we will present “Physician’s perspective on the burden of Chronic Spontaneous Urticaria (CSU) for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices” and “Impact of chronic spontaneous urticaria on health-related quality of life domains: Country-specific data from patients participating in the Urticaria Voices study.
 
 

 
 

BConference.jpg

World Bronchiectasis Conference in Dundee, Scotland

From July 4-6, 2024 GAAPP and more than 15 other organizations and patient advocacy groups focused on bronchiectasis, NTM, and other respiratory conditions, participating in World Bronchiectasis Conference in Dundee, Scotland.

Click here to hear from leading global experts and learn more about managing bronchiectasis.

 
 

 
 

Relevant News

 
 

CAAT logo.jpg

A recent study evaluated the effectiveness of the Moroccan Arabic version of the COPD Assessment Test (CAT) in screening for chronic obstructive pulmonary disease (COPD) among Arabic-speaking populations. The results demonstrated that the CAT (and its recently rebranded version the CAAT) could effectively serve as a screening tool for COPD, aiding healthcare professionals in primary care settings to diagnose the disease earlier.

To support our Arabic speaking community members, GAAPP released a new educational video in Arabic and posted a translation of the CAAT on the CAAT webpage. We greatly appreciate Dr. Arafa Aboelhassan for recording the video.

The CAAT educational postcard aiming to raise awareness of this important tool is now available for downloading on the webpage. A hard copy will be available at our conference booths.

 For more information, click here.

 
 

 
 

From the Chief Scientific Officer Desk

 
 
IMG_1966.jpg

July’s highlight was the third World Bronchiectasis Day that focused on the importance of patient engagement and participation in clinical trials. This critical role was highly evident at the World Bronchiectasis Conference in Dundee, UK where we heard about several successful early and late stage clinical trials with novel potential treatments for people with non-CF bronchiectasis.

Innovation in Respiratory treatment requires progression of better drug development tools that assess trial outcomes that matter to patients including symptoms like cough and mucus (phlegm) production. Industry supporters of the CAAT validation in non-CF bronchiectasis through the EMBARC BRIDGE study met at the World Bronchiectasis Conference to discuss the Regulatory strategy supporting the validation efforts. The outcome will be discussed with the CAAT Governance Board in August.

We invite you to complete our membership survey, as your feedback is essential for GAAPP’s work in the future.

Chief Scientific Officer Ruth Tal-Singer, PhD

 
 

 
 

Facebook X Logo LinkedIn YouTube TikTok YouTube Threads

 
 

GAAPP_logo_v2_color.png

Altgasse 8-10, 1130, Vienna, Austria
+43 (0) 6767534200
info@gaapp.org  | www.gaapp.org